reported the results of a phase II clinical trial evaluating the effect of ICI (pembrolizumab) plus chemotherapy (docetaxel) vs chemotherapy (docetaxel) alone in previously treated patients with advanced NSCLC, including patients with sensitizing EGFR mutations who had experienced disease progression after platinum-based chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.